CCL2 and systemic sclerosis: Several studies have identified potential circulating biomarkers associated with accelerated SSc-ILD progression, including interleukin (IL)-6 [11], C-reactive protein (CRP) [12], monocyte chemoattractant protein-1 (MCP-1) [13], CC chemokine ligand 18 (CCL18) [14, 15], and CXCL4 [16].